What analysts say:
- Buy, sell, or hold?: Analysts strongly back Zep, with three of five rating it a buy and the remainder rating it a hold. Analysts like Zep better than competitor Clorox Company overall. Zep's rating hasn't changed over the past three months.
- Revenue Forecasts: On average, analysts predict $175.6 million in revenue this quarter. That would represent a rise of 8.8% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of 37 cents per share. Estimates range from 36 cents to 39 cents.
What our community says:
CAPS All Stars are solidly behind the stock with 90% granting it an "outperform" rating. The community at large backs the All Stars with 89.1% assigning it a rating of "outperform." Fools have embraced Zep, though the message boards have been quiet lately with only 21 posts in the past 30 days. Though still bullish, the CAPS rating of four out of five stars for Zep is a bit more pessimistic than the community assessment.
Zep's profit has risen year over year by an average of 33.8% over the past five quarters. Revenue has now gone up for three straight quarters. The company's gross margin shrank by 2.7 percentage points in the last quarter. Revenue rose 9.7% while cost of sales rose 15.6% to $89.6 million from a year earlier.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Zep now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.